0001209191-20-005130.txt : 20200128 0001209191-20-005130.hdr.sgml : 20200128 20200128161300 ACCESSION NUMBER: 0001209191-20-005130 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200124 FILED AS OF DATE: 20200128 DATE AS OF CHANGE: 20200128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Allen Patricia L CENTRAL INDEX KEY: 0001348587 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 20554348 BUSINESS ADDRESS: BUSINESS PHONE: 978-687-6988 MAIL ADDRESS: STREET 1: 7 ASHFORD LANE CITY: ANDOVER STATE: MA ZIP: 01810 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-24 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001348587 Allen Patricia L C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 1 0 0 0 Common Stock 2020-01-24 4 C 0 25000 3.95 A 25000 D Common Stock 2020-01-24 4 S 0 17804 65.933 D 7196 D Common Stock 2020-01-24 4 S 0 6496 66.5491 D 700 D Common Stock 2020-01-24 4 S 0 700 67.3586 D 0 D Stock Option (Right to Buy) 3.95 2020-01-24 4 A 0 25000 0.00 A 2026-09-26 Common Stock 25000 10233 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.25 to $66.24, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.25 to $67.12, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.29 to $67.45, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This stock option award was issued pursuant to the Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 27, 2016, subject to continued service through such dates. /s/ Thomas P. Kelly, Attorney-in-Fact 2020-01-28